Marc Duey - May 16, 2022 Form 3 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role: Director
Signature: /s/ Scott M. Coiante, attorney-in-fact
Stock symbol: APRE
Transactions as of: May 16, 2022
Transactions value $: $0
Form type: 3
Date filed: 5/26/2022, 04:15 PM
Next filing: Aug 1, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	APRE	Common Stock						152K	May 16, 2022	Direct
holding	APRE	Common Stock						439	May 16, 2022	By spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	APRE	Stock Option (right to buy)	May 16, 2022	Common Stock	51.2K	$0.44	Direct
holding	APRE	Series A Non-Voting Convertible Preferred Stock	May 16, 2022	Common Stock	401K		Direct	F1
holding	APRE	Series A Non-Voting Convertible Preferred Stock	May 16, 2022	Common Stock	1.16K		By spouse	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Following stockholder approval at the Issuer's annual stockholder's meeting, each share of Series A Non-Voting Convertible Preferred Stock is convertible into 10 shares of the Issuer's common stock ("Common Stock") at any time at the option of the holder thereof, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. The Series A Non-Voting Convertible Preferred Stock has no expiration date.

Content

Following stockholder approval at the Issuer's annual stockholder's meeting, each share of Series A Non-Voting Convertible Preferred Stock is convertible into 10 shares of the Issuer's common stock ("Common Stock") at any time at the option of the holder thereof, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. The Series A Non-Voting Convertible Preferred Stock has no expiration date.

Remarks:

Exhibit 24 - Power of Attorney